Genetic cause of hyperglycaemia and response to treatment in diabetes

@article{Pearson2003GeneticCO,
  title={Genetic cause of hyperglycaemia and response to treatment in diabetes},
  author={Ewan R. Pearson and Bryan J. Starkey and Roy J Powell and Fiona M. Gribble and Penelope M.S. Clark and Andrew T. Hattersley},
  journal={The Lancet},
  year={2003},
  volume={362},
  pages={1275-1281}
}
BACKGROUND Type 2 diabetes shows evidence of underlying heterogeneity. No studies have assessed whether different causes for diabetes change the response to oral hypoglycaemic therapy. In a few cases, patients with diabetes caused by mutations in the hepatocyte nuclear factor 1alpha (HNF-1alpha) gene have been described as sensitive to the hypoglycaemic effects of sulphonylureas. We aimed to see whether the glycaemic response to the sulphonylurea gliclazide and the biguanide metformin differed… Expand

Paper Mentions

Observational Clinical Trial
Monogenic diabetes is an unusual form of diabetes. It usually presents in patients under the age of 30, so is often misdiagnosed as Type 1 diabetes which is more common. Patients with… Expand
ConditionsDiabetes
InterventionOther
Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes.
This review focuses on current evidence for pharmacogenetics for the 3 commonly used drug classes in treating diabetes: metformin, sulphonylureas and thiazolidinediones. Currently, metforminExpand
Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies.
TLDR
It is not totally clear whether monotherapy should be pursued until the maximally effective dose of a given drug or combination therapy should be used to target distinct pathogenic defects in a single patient. Expand
The impact of low dose gliclazide on the incretin effect and indices of beta cell function.
TLDR
Low dose gliclazide reduces plasma glucose in response to oral glucose load, with concomitant augmentation of the classical incretin effect, and beta-cell modelling shows that low plasma concentrations of glicLazide potentiate late phase insulin secretion and increase glucose sensitivity by 50%. Expand
Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China
TLDR
This study demonstrated that the CDKN2A/CDKN2B gene may be nominally associated with the efficacy of glibenclamide, and that CDKN1/CD KN2B is associated with beta cell function. Expand
Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes.
TLDR
It seems that the genes responsible for the development of diabetes may not be the same driving disease progression after the diagnosis has been made, and pharmacogenetic interactions explain some of the interindividual variation in responses to antidiabetic treatment and may provide the foundation for future genotype-based treatment standards. Expand
Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia
TLDR
HbA1c was no higher than in untreated patients and did not change when therapy was discontinued, suggesting no impact on glycaemia, and is likely to reflect the regulated hyperglycaemia seen in patients owing to their glucose sensing defect and is an example of pharmacogenetics. Expand
Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms
  • C. Aquilante
  • Medicine
  • Expert review of cardiovascular therapy
  • 2010
TLDR
The purpose of this review is to discuss sulfonylurea pharmacogenomics in the setting of Type 2 diabetes, specifically focusing on polymorphisms in drug target and diabetes risk genes, and their relationship with interindividual variability in sulfonyLurea response and adverse effects. Expand
Pharmacogenetics and target identification in diabetes.
  • E. Pearson
  • Biology, Medicine
  • Current opinion in genetics & development
  • 2018
TLDR
Over the next few years, increasing cohort sizes and linkage at scale to electronic medical records will provide considerable potential for stratification and novel target identification in diabetes. Expand
β-Cell Dysfunction, Insulin Sensitivity, and Glycosuria Precede Diabetes in Hepatocyte Nuclear Factor-1α Mutation Carriers
TLDR
It is concluded that marked β-cell deficiency, increased insulin sensitivity, and a low renal threshold are present in young nondiabetic HNF-1α mutation carriers and the presence of glycosuria post–glucose load could be used to screen children of mutation carriers. Expand
Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes.
TLDR
The defining of molecular genetic etiology in monogenic diabetes has identified several specific beta-cell defects, and these are critical in determining the response to treatment, and are reviewed how genetic knowledge alters treatment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Different genes, different diabetes: lessons from maturity-onset diabetes of the young
TLDR
Differences in prognosis and treatment strongly support the increased use of molecular genetic testing in diabetes. Expand
Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state
TLDR
Whereas subjects with positive GADA or Type II diabetes have impaired insulin sensitivity with increasing glucose concentrations, MODY mutation carriers seem to be protected from the effect of glucose toxicity. Expand
Altered Insulin Secretory Responses to Glucose in Diabetic and Nondiabetic Subjects With Mutations in the Diabetes Susceptibility Gene MODY3 on Chromosome 12
TLDR
In nondiabetic MODY3 subjects insulin secretion demonstrates a diminished ability to respond when blood glucose exceeds 8 mmol/l, and β-cell dysfunction is present before the onset of overt hyperglycemia in this form of MODY. Expand
Efficacy of metformin in the treatment of NIDDM. Meta-analysis.
TLDR
Metformin and sulfonylurea have an equal effect on fasting blood glucose and glycosylated hemoglobin, but the body weight is significantly lower after metformin compared with sulfonyLurea treatment because of an increase in body weight after sulfony luresa treatment. Expand
Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3).
TLDR
It is shown that despite a profound defect in glucose-stimulated insulin secretion, diabetic Hnf-1alpha(-/-) mice have a robust glibenclamide-induced insulin secretory response, suggesting that hypersensitivity to sulfonylureas in MODY3 patients may be due to impaired hepatic clearance and elevated plasma concentrations of the drug. Expand
Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program
TLDR
Three cases illustrate that pentoxifylline, in conjunction with intensive therapy for diabetes, may be particularly useful in reducing significant proteinuria in patients with macroalbuminuria from diabetic nephropathy. Expand
Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect.
TLDR
It is suggested that mutations at the MODY3/NIDDM2 gene(s) result in a reduced insulin secretory response, that subsequently progresses to diabetes and underlines the importance of subphenotypic classification in studies of diabetes. Expand
Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes
TLDR
The HOMA-CIGMA test with immunoreactive insulin provides similar information in distinguishing insulin sensitivity between subjects with normal glucose tolerance, those with impaired glucose tolerance and those with Type II diabetes as does FSIVGTT, whereas ITT is less informative. Expand
Pharmacogenetics of Tolbutamide Metabolism in Humans
TLDR
Evidence is provided for monogenic control of tolbutamide metabolism in man and the results suggest that fixed dosage regimens of this drug, as were prescribed in the controversial University Group Diabetes Program study, might lead to higher accrued blood levels in slow inactivators. Expand
beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors.
TLDR
Mutations in transcription factors expressed in the beta-cell are the major cause of MODY, and the phenotype clearly varies with the gene that is mutated, there is little evidence to indicate that different mutations within the same gene have different phenotypes. Expand
...
1
2
3
4
...